Improved guided bone regeneration by combined application of unmodified, fresh autologous adipose derived regenerative cells and plasma rich in growth factors: A first-in-human case report and literature review

Table 1 Overview on the treatments performed in the present study.

Treatments	Time point	Procedures
Pre-phase	T0	Evaluation of the patient
Preparatory steps	T1 (4 mo after T0)	Preparation of plasma rich in growth factors (PRGF-2); isolation of unmodified, autologous adipose derived regenerative cells (UA-ADRCs)
1	T1 (GBR-MSA)	Extraction of tooth # 14; ridge preservation and external sinus lift procedures
2	T2 (6 wk after T1)	Extraction of teeth # 11, #12 and #22; collection of the first biopsies
3	T3 (34 wk after T1)	Placement of implants; collection of the second biopsies
4	T4 (1 yr after T3)	Extraction of tooth #18; placement of healing abutments
5	T5 (6 wk after T4)	Placement of the definitive prosthetic telescopic bridge
	T6 (32 mo after T1)	Last radiologic follow-up

In order to prevent potential identification of the patient the timeline was coded.

Table 2 Details of antibodies and incubation protocols used in the present study

Antibody	Isotype	Manufacturer	Dilution/incubation
runX2	Goat polyclonal	Santa Cruz Biotechnology (Dallas, TX, United States)	1:30, 4 °C, ON
Collagen type I	Rabbit monoclonal	Abcam (Cambridge, United Kingdom)	1:400, RT, 1 h
Alkaline phosphatase	Rabbit polyclonal	Quartett (Berlin, Germany)	Ready to use, 4 °C, ON
Von Willebrand factor	Rabbit polyclonal	Linaris (Dossenheim, Germany)	1:200, RT, 1h
CD146	Rabbit monoclonal	Abcam	1:50, RT, 1h
CD73	Mouse monoclonal	Antibodies-online (Atlanta, GA, United States)	1:100, 4 °C, ON
PPARγ	Mouse monoclonal	Santa Cruz Biotechnology	1:25, 4 °C, ON

ON: Overnight; RT: Room temperature.